InvestorsHub Logo
Followers 10
Posts 1578
Boards Moderated 0
Alias Born 10/15/2014

Re: Serenity3 post# 11939

Tuesday, 06/13/2017 12:28:21 PM

Tuesday, June 13, 2017 12:28:21 PM

Post# of 16885
On the pain question, it's entirely Braeburn's responsibility under the license agreement. I heard from Titan's management back in March that there was no pain trial going on. That was odd, because Braeburn's S-1 stated they had started enrollment for one, but maybe it was dropped.

In my opinion, pain is on the backburner for Braeburn because there is no competitive implant on the horizon. They are going forward with pain for injectables because Indivior is doing so, and they don't want to Indivior to have a competitive advantage.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent TTNP News